Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The management of metastatic GIST: current standard and investigational therapeutics.J Hematol Oncol. 2021; 14: 2
- Molecular target therapy for gastrointestinal stromal tumors.Translational Gastrointest Cancer. 2015; 4: 207-218
- Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates.Curr Treat Options Oncol. 2020; 21: 55
- Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFRalpha mutation in a metastatic GIST patient responding to imatinib.Sci Rep. 2019; 9: 2172
- New frontiers in the medical management of gastrointestinal stromal tumours.Ther Adv Med Oncol. 2019; 11 (1758835919841946)
- Secondary KIT mutations: the GIST of drug resistance and sensitivity.Br J Cancer. 2019; 120: 577-578
- Early and next-generation KIT/PDGFRA kinase inhibitors and the future of treatment for advanced gastrointestinal stromal tumor.Front Oncol. 2021; 11: 672500
- Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA Variants.Cancer Cell. 2019; 35: 738-751 e9
- Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens.Ann Oncol. 2018; 29: viii576-viii577
- Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Oncol. 2020; 21: 923-934
- Ripretinib for the treatment of advanced gastrointestinal stromal tumor.Therap Adv Gastroenterol. 2021; 14 (17562848211008177)
- Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.Eur J Cancer. 2021; 155: 236-244
News in Brief in Cancer Discovery: Testing Ripretinib against Sunitinib in GIST. Cancer Discov. 2022 Mar 1;12(3):591-592. doi: 10.1158/2159-8290.CD-NB2022-0004. PMID: 35086925.
Evans EK., Gardino AK., Kim JL., et al.,. A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci Transl Med. 2017 Nov 1;9(414):eaao1690. doi: 10.1126/scitranslmed.aao1690. PMID: 29093181.
- Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal stromal tumors.Clin Cancer Res. 2019; 25: 609-618
- Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.Lancet Oncol. 2020; 21: 935-946
- Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).J Clin Oncol. 2019; 37: 11022
- Avapritinib in patients with advanced gastrointestinal stromal tumors following at least three prior lines of therapy.Oncologist. 2021; 26: e639-e649
Heinrich M vMM, Jones RL. Avapritinib is highly active and well-tolerated in patients (pts) with advanced GIST driven by diverse variety of oncogenic mutations in KIT and PDGFRA. Presented at the Connective Tissue Oncology Society Annual meeting (CTOS), Nov 14-17th 2018, Rome, Italy
- Pleomorphic liposarcoma: clinical observations and molecular variables.Cancer. 2011; 117: 5359-5369
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.Lancet Oncol. 2014; 15: 415-423
- Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival.Ann Oncol. 2012; 23: 1601-1607
- Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard.Scientific Rep. 2017; 7: 11836
Thirasastr P AB, Lin H, Roland C, Feig B, Keung E et al. Efficacy of Gemcitabine- Docetaxel in Dedifferentiated Liposarcoma. presented at the Connective Tissue Oncology Society (CTOS) Annual Virtual Meeting, Nov 16-19th 2021.
- Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].J Clin Oncol. 2007; 25 (Electronic)): 1527-7755
- Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial.J Clin Oncol. 2016; 34: 786-793
- Eribulin -- a review of preclinical and clinical studies.Crit Rev Oncol Hematol. 2012; 81: 163-184
- Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.Lancet Oncol. 2011; 12: 1045-1052
- Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.Lancet. 2016; 387: 1629-1637
- Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III Study of Eribulin Versus Dacarbazine.J Clin Oncol. 2017; 35: 3433-3439
- FDA approval summary: eribulin for patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.Clin Cancer Res. 2017; 23 (Electronic)): 1557-3265
- Nuclear transport and cancer: from mechanism to intervention.Nat Rev Cancer. 2004; 4: 106-117
- Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.Oncotarget. 2017; 8: 7521-7532
Gounder MRA, Somaiah N, et al. A phase 2/3, randomized, double blind, cross-over, study of selinexor versus placebo in advanced unresectable dedifferentiated liposarcoma. Presented at the Connective Tissue Oncology Society (CTOS) Annual Virtual Meeting, Nov 18-21st 2020. Abstract 20.
- First-in-class, first-in-human phase i study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors.J Clin Oncol. 2016; 34: 4142-4150
- Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.Future Oncol. 2021; 17: 2923-2939
- Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network.PLoS One. 1932; 2021 (Electronic)): 6203
- SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas.Cancer Res. 2005; 65 (0008-5472 (Print)): 4012-4019
- Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group.Am J Clin Pathol. 2009; 131: 222-227
- Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits.Mol Cell. 1999; 3: 247-253
- Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation.Cancer Cell. 2010; (Electronic)): 1878-3686
- SELNET clinical practice guidelines for soft tissue sarcoma and GIST.Cancer Treat Rev. 2022; 102 (Electronic)): 102312
- NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021.J Natl Compr Canc Netw. 2020; 18: 1604-1612
- Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.JAMA Oncol. 2018; 4: e180219
- European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.Clin Oncol (R Coll Radiol). 2018; 30: 448-454
- Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi-institutional analysis.Oncology. 2014; 87: 95-103
- Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.Lancet Oncol. 2018; 19: 649-659
- Mesenchymal neoplasms with NTRK and other kinase gene alterations.Histopathology. 2022; 80: 4-18
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).Cancer Discov. 2017; 7: 400-409
- Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.Lancet Oncol. 2018; 19: 705-714
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.Lancet Oncol. 2020; 21: 531-540
- Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.ESMO Open. 2021; 6: 100113
- Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications.ESMO Open. 2021; 6 (2059-7029 (Electronic)): 100072
- The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients.Eur J Cancer. 2020; 127 (1879-0852(Electronic)): 96-107
- Sorafenib for Advanced and Refractory Desmoid Tumors.N Engl J Med. 2018; 379: 2417-2428
- Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.Lancet Oncol. 2019; 20: 1263-1272
- Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor.Ann Surg Oncol. 2018; 25: 768-775
- Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors.Eur J Cancer. 2015; 51 (1879-0852 (Electronic)): 210-217
- Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study.Lancet Oncol. 2019; 20: 877-886
- A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells.Proc Natl Acad Sci U S A. 2006; 103: 690-695
- Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).Ann Oncol. 2008; 19 (1569-8041 (Electronic)): 821-822
- Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.Cancer. 2012; 118 (1097-0142 (Electronic)): 1649-1655
- CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.Lancet Oncol. 2015; 16: 949-956
- Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial.Lancet Oncol. 2018; 19: 639-648
- Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.N Engl J Med. 2015; 373: 428-437
- Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.Lancet. 2019; 394: 478-487
- Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT).PLoS One. 2020; 15: e0233046
- PEComa.in: WHO classification of tumors editorial board. Soft tissue and bone tumours. International Agency for Research on Cancer, Lyon (France)2020: 312-314
- Perivascular epithelioid cell neoplasms: pathology and pathogenesis.Hum Pathol. 2010; 41: 1-15
- Ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities.Cancer. 2021; 127: 2934-2942
- Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms.Hum Pathol. 2007; 38: 1361-1371
- Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours.Nat Rev Clin Oncol. 2018; 15 (1759-4782 (Electronic)): 443-458
- Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).Clin Cancer Res. 2019; 25: 5295-5300
- Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.J Clin Oncol. 2010; 28: 835-840
- nab-Sirolimus for patients with malignant perivascular epithelioid cell tumors.J Clin Oncol. 2021; 39: 3660-3670
- Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology.Lab Invest. 2019; 99: 1309-1320
- Mdm2-mediated ubiquitylation: p53 and beyond.Cell Death Differ. 2010; 17: 93-102
- Treating cancer with selective CDK4/6 inhibitors.Nat Rev Clin Oncol. 2016; 13: 417-430
- Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.J Clin Oncol. 2013; 31: 2024-2028
- Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.JAMA Oncol. 2016; 2: 937-940
- Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma.J Clin Oncol. 2019; 37: 11004
von Mehren M., Kane JM., Bui MM., et al., NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. J Natl Compr Canc Netw. 2020 Dec 2;18(12):1604-1612. doi: 10.6004/jnccn.2020.0058. PMID: 33285515.
- Synovial sarcoma: a clinical review.Curr Oncol. 2021; 28: 1909-1920
- Synovial sarcoma mechanisms: a series of unfortunate events.Cell. 2013; 153: 11-12
- Molecular detection of the synovial sarcoma translocation t(X;18) by real-time polymerase chain reaction in paraffin-embedded material.Diagn Mol Pathol. 2002; 11: 16-21
- Nuclear expression of DDIT3 distinguishes high-grade myxoid liposarcoma from other round cell sarcomas.Mod Pathol. 2021; 34: 1367-1372
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.Lancet Oncol. 2017; 18: 1493-1501
- NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.Mod Pathol. 2012; 25: 854-858
- Targeting cancer testis antigens in synovial sarcoma.J Immunother Cancer. 2021; 9: e002072
- Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7.Int J Cancer. 2001; 94: 252-256
- Adoptive cellular therapies: the current landscape.Virchows Arch. 2019; 474: 449-461
- A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.Clin Cancer Res. 2015; 21: 1019-1027
- Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 (c259)T Cells in Synovial Sarcoma.Cancer Discov. 2018; 8: 944-957
- Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.Lancet Oncol. 2018; 19: 416-426
- Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.JAMA Oncol. 2018; 4: 93-97
- Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.J Immunother Cancer. 2017; 5: 100
- Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.Lancet Oncol. 2019; 20: 837-848
- A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas.J Clin Oncol. 2020; 38: 11509
- Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).J Clin Oncol. 2021; 39: 11519
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
